Characterisation of the Novel HLA-C*06:406 Allele by Sequencing-Based Typing.
HLA-C*06:406 differs from HLA-C*06:02:01:01 by one nucleotide substitution in codon 201 in exon 4.
Humans↗
SEARCH · PubMed Health
Results for “sequence based typing”
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Characterisation of the Novel HLA-DRB3*02:238 Allele by Sequencing-Based Typing.
HLA-DRB3*02:238 differs from HLA-DRB3*02:24 by one nucleotide substitution in codon 60 in exon 2.
Humans↗
Characterisation of the Novel HLA-C*03:703 Allele by Sequencing-Based Typing.
HLA-C*03:703 differs from HLA-C*03:620 by one nucleotide substitution in codon 114 in exon 3.
Humans↗
Characterisation of the Novel HLA-DPB1*1784:01 Allele by Sequencing-Based Typing.
HLA-DPB1*1784:01 differs from HLA-DPB1*514:01 by one nucleotide substitution in codon 57 in exon 2.
Humans↗
Characterisation of the Novel HLA-DQB1*06:03:57 Allele by Sequencing-Based Typing.
HLA-DQB1*06:03:57 differs from HLA-DQB1*06:03:01:01 by one nucleotide substitution in codon 21 in exon 2.
Humans↗
Characterisation of the Novel HLA-C*07:1187 Allele by Sequencing-Based Typing.
HLA-C*07:1187 differs from HLA-C*07:02:01:01 by one nucleotide substitution in codon 304 in exon 5.
Humans↗
Characterisation of the Novel HLA-DRB4*01:193 Allele by Sequencing-Based Typing.
HLA-DRB4*01:193 differs from HLA-DRB4*01:03:01:01 by one nucleotide substitution in codon 166 in exon 3.
Humans↗
Characterisation of the Novel HLA-DRB1*09:01:18 Allele by Sequencing-Based Typing.
HLA-DRB1*09:01:18 differs from HLA-DRB1*09:01:02:01 by one nucleotide substitution in codon 44 in exon 2.
Humans↗
Characterisation of the Novel HLA-B*44:357:02 Allele by Sequencing-Based Typing.
HLA-B*44:357:02 differs from HLA-B*44:357:01 by one nucleotide substitution in codon 160 in exon 3.
Humans↗
Characterisation of the Novel HLA-C*07:1184 Allele by Sequencing-Based Typing.
HLA-C*07:1184 differs from HLA-C*07:01:01:01 by one nucleotide substitution in codon-18 in exon 1.
Humans↗
Characterisation of the Novel HLA-B*27:05:64 Allele by Sequencing-Based Typing.
HLA-B*27:05:64 differs from HLA-B*27:05:02:05 by one nucleotide substitution in codon -21 in exon 1.
Humans↗
Characterisation of the Novel HLA-C*14:168 Allele by Two Different Sequencing-Based Typing Techniques.
The novel HLA-C*14:168 allele differs from HLA-C*14:02:01:02 by three nucleotides in exon 7.
Humans↗
Characterisation of the Novel HLA-B*40:01:02:68Q Allele by Sequencing-Based Typing.
HLA-B*40:01:02:68Q differs from HLA-B*40:01:02:01 by one nucleotide substitution in intron 2 at the splice site with exon 3.
Humans↗
Characterisation of a Novel HLA-A*02:558 Allele by Sequencing-Based Typing in a Chinese Individual.
HLA-A*02:558 differs from HLA-A*02:06:01:01 by one nucleotide substitution in codon 96 in exon 3.
Humans↗
Characterisation of the Novel HLA-A*68:02:26 Allele by Sequencing-Based Typing.
The novel allele A*68:02:26 differs from A*68:02:01:01 by one nucleotide substitution in exon 8.
Humans↗
Characterisation of the Novel HLA-DRB1*13:371 Allele by Sequencing-Based Typing.
The novel allele HLA-DRB1*13:371 differs from HLA-DRB1*13:02:01:01 by one nucleotide substitution in codon 127 in exon 3.
Humans↗
Characterisation of the Novel HLA-A*68:326 and -C*02:254N Alleles by Two Different Sequencing-Based Typing Techniques.
Novel alleles HLA-A*68:326 and -C*02:254N carry exonic mutations causing amino acid change or truncation.
Humans↗
HLA class II "typing": direct sequencing of DRB, DQB, and DQA genes.
Routine clinical HLA class II typing is based largely on serological and cellular methods. These methods have many drawbacks that have led to the evaluation of molecular approaches to typing, including restriction fragment length polymorphism studies and oligotyping. We present here an alternative molecular approach, sequence-based typing (SBT), that allows direct determination of the sequences of all HLA class II polymorphic genes, thus providing the most detailed information currently possible in this regard. The data presented here using SBT are based on direct sequencing of polymerase chain reaction (PCR)-amplified DRB, DQB, and DQA cDNAs using a limited number of oligonucleotides. The oligonucleotides are designed to allow simultaneous determination of allelic sequences in any heterozygote as well as characterization of DRB isotypic complexity. Two types of amplification oligonucleotides (nonconserved and/or conserved) are used for DRB typing, which involves a maximum of four simultaneous cDNA/PCR/sequencing reactions. The first of these reactions only uses conserved oligonucleotides and is designed to detect all the different DRB transcripts present in any given heterozygote; the other three reactions use nonconserved oligonucleotides and are designed to ensure the unambiguous interpretation of the most complex DRB heterozygote combinations. Characterization of DQA1 and DQB1 sequences can be performed by using conserved oligonucleotides and only involves one reaction per locus. We have applied SBT to 43 homozygous cell lines and to 38 different heterozygote combinations that had previously been serologically typed. In all cases we were able to determine the allelic composition at DRB1, DRB3/4/5 and/or DQB1, and DQA1 loci of these cell lines and subjects; our results, analyzed by blind protocol, were consistent with the serological phenotypes. SBT can be extended to class I and class III genes and is automatable. We believe that this strategy deserves further evaluation as a possible HLA typing method.
Base Sequence↗